These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. Fisher RI; Terry WD; Hodes RJ; Rosenberg SA; Makuch R; Gordon HG; Fisher SG Surg Clin North Am; 1981 Dec; 61(6):1267-77. PubMed ID: 7031934 [No Abstract] [Full Text] [Related]
9. Adjuvant BCG immunotherapy for stage I and II malignant melanoma. Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739 [TBL] [Abstract][Full Text] [Related]
10. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma. O'Connor TP; Labandter HP; Hiles RW; Bodenham DC Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132 [TBL] [Abstract][Full Text] [Related]
11. Results of adjuvant BCG immunotherapy in malignant melanoma. Wätzig V; Knopf B Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442 [TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy: an overview. Morton DL Semin Oncol; 1974 Dec; 1(4):297-310. PubMed ID: 4620437 [No Abstract] [Full Text] [Related]
13. Adjuvant immunotherapy with BCG in stage II malignant melanoma. Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725 [TBL] [Abstract][Full Text] [Related]
14. The role of adjuvant therapy in melanoma management. Barth A; Morton DL Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V. Jacquillat C; Banzet P; Civatte J; Puissant A; Cottenot F; Israel L; Belaich S; Chastang C; Maral J Recent Results Cancer Res; 1978; 68():346-58. PubMed ID: 111323 [No Abstract] [Full Text] [Related]
16. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma. Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888 [TBL] [Abstract][Full Text] [Related]
17. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856 [TBL] [Abstract][Full Text] [Related]
18. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548 [TBL] [Abstract][Full Text] [Related]
20. Combined modality therapy of malignant melanoma. Hersh EM; Gutterman JU; McBride CM World J Surg; 1979 Jul; 3(3):329-43. PubMed ID: 382647 [No Abstract] [Full Text] [Related] [Next] [New Search]